About Genmab
About Genmab
Board of Directors
Senior Leadership Team
Corporate Social Responsibility
Partnerships
FAQ
Science & Research
Products In Development
Licensing Opportunities
Clinical Trials
Introduction to Antibodies
Antibody Discovery
Next Generation Technology
Scientific Articles
Investor Center
InvestorPortal
Stock Quotes
Financial Calendar
Stock Information
Analysts
Events
Investor Contact
Corporate Documents
Warrant Scheme
Press Center
Recent News Releases
Archived News Releases
Press Contact
Careers
Career Opportunities
Contact Genmab
Contact Genmab
Subscribe to Genmab News
Hot News
Genmab Reaches Second Milestone in Lundbeck Collaboration...
»
Arzerra Fourth Quarter and Full Year 2011 Net Sales Figures...
»
Genmab Announces Progress with DuoBody™ Platform...
»
Genmab Announces Progress with Lundbeck Collaboration ...
»
More Genmab News Releases
Investor Center
InvestorPortal
Stock Quotes
Financial Calendar
Stock Information
Analysts
Events
Investor Contact
Corporate Documents
Warrant Scheme
Home
Print
Legal Notice
Use of this Site is subject to Important Legal Terms, which you are requested to read prior to proceeding.
© 2011 Genmab A/S
Investor Center » Events » 2011 » Genmab Post-ASH Seminar, London, UK
Genmab Post-ASH Seminar, London, UK
Genmab hosted a seminar to discuss the data it presented at the 2011 Annual Meeting of the Society of Hematology (December 10-13) on December 19, 2011 in London.
Click here for the webcast
.
Click here to view the slides
.
A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT)
A Phase II Trial of Ofatumumab in Subjects with Waldenstrom’s Macroglobulinemia
A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data
(back to Recent News)